Clinical Trials Logo

Clinical Trial Summary

In this study, the tetravalent bioconjugate candidate vaccine Kleb4V will be tested to obtain first-time-in-human (FTIH) data on its safety and immunogenicity in healthy adults.


Clinical Trial Description

Kleb4V is a tetravalent bioconjugate vaccine including O antigen-polysaccharides of the most predominant Klebsiella pneumoniae serotypes, which will be formulated with or without Adjuvant System, AS03. Study participants will be randomized towards Kleb4V Low dose with or without AS03, Kleb4V Target dose with or without AS03, or placebo. The study will be conducted in two steps. In Step1 (safety cohort): safety and tolerability of Kleb4V without and with Adjuvant AS03 will be evaluated first in adults of 18-40 y, and subsequently in the target population of older adults 55-70 y. Enrolment will be staggered in groups of small numbers to the different doses and formulations. In Step 2 (target cohort): Older adults (55-70y) will be concomitantly randomized to receive 1 of the 4 different vaccine formulations or placebo. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04959344
Study type Interventional
Source LimmaTech Biologics AG
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 5, 2021
Completion date September 26, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04413305 - WGS-guided Tracking and Infection Control Measures of CRKP N/A
Recruiting NCT03598543 - Epidemiology of Klebsiella Pneumoniae in China
Not yet recruiting NCT03245632 - Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China N/A
Recruiting NCT03891433 - Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae Phase 4